AI-Powered Precision Decision-Making for Pancreatic Diseases

This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.

NCT Number	NCT07439757
Lead Sponsor	Changhai Hospital Collaborators: The First Affiliated Hospital with Nanjing Medical University, The Affiliated People's Hospital of Ningbo University, The Second Affiliated Hospital of Jiaxing University, Shanghai Changzheng Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shengjing Hospital, Shanghai Fourth People's Hospital Tongji University, First Affiliated Hospital of Zhejiang University, Shanghai Fudan University Cancer Center
Conditions	Pancreatic Cancer, Diagnose Disease, IPMN, Pancreatic, Pancreatic Cystic Lesions, Chronic Pancreatitis, Pancreatic Neuroendocrine Tumor, Acute Pancreatitis (AP)
Enrollment	2,000 participants
Start Date	2026-03-01
Primary Completion	2029-10-31 (estimated)
Study Completion	2029-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-27